Vaccines: Manufacturing Industries

Department for Business, Energy and Industrial Strategy written question – answered on 12th February 2021.

Alert me about debates like this

Photo of Chi Onwurah Chi Onwurah Shadow Minister (Business, Energy and Industrial Strategy), Shadow Minister (Digital, Culture, Media and Sport)

To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps he is taking to increase the UK’s long-term vaccine manufacturing capacity.

Photo of Nadhim Zahawi Nadhim Zahawi Parliamentary Under-Secretary (Department for Business, Energy and Industrial Strategy), The Parliamentary Under-Secretary for Health and Social Care

The Government has invested over £300 million to secure and scale up the UK’s manufacturing capabilities to be able to respond to the pandemic. This includes:

a) Facilities that have come online:

  • £4.7 million for skills training through the Advanced Therapies Skills Training Network, which will be delivered through both virtual and physical centres;
  • £8.75 million for the set-up of the rapid deployment facility at Oxford Biomedica in Oxfordshire;
  • £65.5 million for the early manufacture of the University of Oxford / AstraZeneca vaccine; and
  • Funding for fill and finish through a contract with Wockhardt in Wrexham, North Wales which is currently providing fill and finish capabilities to the University of Oxford / AstraZeneca vaccine.

b) Facilities that will come online later this year, to help provide longer term UK capacity:

In addition to the above, we have also funded the expansion of the Valneva factory in Livingston, Scotland.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.